123 related articles for article (PubMed ID: 11115556)
41. BARD1: an independent predictor of survival in non-small cell lung cancer.
Zhang YQ; Bianco A; Malkinson AM; Leoni VP; Frau G; De Rosa N; André PA; Versace R; Boulvain M; Laurent GJ; Atzori L; Irminger-Finger I
Int J Cancer; 2012 Jul; 131(1):83-94. PubMed ID: 21815143
[TBL] [Abstract][Full Text] [Related]
42. Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer.
Tokunaga E; Yamashita N; Kitao H; Tanaka K; Taketani K; Inoue Y; Saeki H; Oki E; Oda Y; Maehara Y
Breast; 2016 Feb; 25():62-8. PubMed ID: 26577950
[TBL] [Abstract][Full Text] [Related]
43. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
[TBL] [Abstract][Full Text] [Related]
44. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
45. Expression of mdm-2 oncoprotein in the primary and metastatic sites of mammary tumor (GI-101) implanted athymic nude mice.
Rathinavelu P; Malavé A; Raney SR; Hurst J; Roberson CT; Rathinavelu A
Cancer Biochem Biophys; 1999 Jul; 17(1-2):133-46. PubMed ID: 10738909
[TBL] [Abstract][Full Text] [Related]
46. Gene expression array analyses predict increased proto-oncogene expression in MMTV induced mammary tumors.
Popken-Harris P; Kirchhof N; Harrison B; Harris LF
Virus Res; 2006 Aug; 119(2):177-86. PubMed ID: 16469401
[TBL] [Abstract][Full Text] [Related]
47. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
48. Malignant transformation by the eukaryotic translation initiation factor 3 subunit p48 (eIF3e).
Mayeur GL; Hershey JW
FEBS Lett; 2002 Mar; 514(1):49-54. PubMed ID: 11904180
[TBL] [Abstract][Full Text] [Related]
49. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
[TBL] [Abstract][Full Text] [Related]
50. hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas.
Xinarianos G; Liloglou T; Prime W; Maloney P; Callaghan J; Fielding P; Gosney JR; Field JK
Cancer Res; 2000 Aug; 60(15):4216-21. PubMed ID: 10945633
[TBL] [Abstract][Full Text] [Related]
51. Prognostic role of TPL2 in early‑stage non‑small cell lung cancer.
Boldrini L; Giordano M; Servadio A; Niccoli C; Bertoglio P; Lucchi M; Melfi F; Mussi A; Fontanini G
Mol Med Rep; 2017 Jun; 15(6):3451-3458. PubMed ID: 28393206
[TBL] [Abstract][Full Text] [Related]
52. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.
Nupponen NN; Porkka K; Kakkola L; Tanner M; Persson K; Borg A; Isola J; Visakorpi T
Am J Pathol; 1999 Jun; 154(6):1777-83. PubMed ID: 10362802
[TBL] [Abstract][Full Text] [Related]
53. High-density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas.
Tran YK; Newsham IF
Cancer Res; 1996 Jul; 56(13):2916-21. PubMed ID: 8674040
[TBL] [Abstract][Full Text] [Related]
54. Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors.
Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Koutroumbi E; Markopoulos C; Gogas J; Kittas C
Anticancer Res; 2001; 21(2A):991-9. PubMed ID: 11396193
[TBL] [Abstract][Full Text] [Related]
55. Mining CK2 in cancer.
Ortega CE; Seidner Y; Dominguez I
PLoS One; 2014; 9(12):e115609. PubMed ID: 25541719
[TBL] [Abstract][Full Text] [Related]
56. eIF3 targets cell-proliferation messenger RNAs for translational activation or repression.
Lee AS; Kranzusch PJ; Cate JH
Nature; 2015 Jun; 522(7554):111-4. PubMed ID: 25849773
[TBL] [Abstract][Full Text] [Related]
57. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
Hollmann CA; Kittrell FS; Medina D; Butel JS
Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
[TBL] [Abstract][Full Text] [Related]
58. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation.
Kittiniyom K; Mastronardi M; Roemer M; Wells WA; Greenberg ER; Titus-Ernstoff L; Newsham IF
Genes Chromosomes Cancer; 2004 Jul; 40(3):190-203. PubMed ID: 15138999
[TBL] [Abstract][Full Text] [Related]
59. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice.
Kitsberg DI; Leder P
Oncogene; 1996 Dec; 13(12):2507-15. PubMed ID: 9000125
[TBL] [Abstract][Full Text] [Related]
60. Loss of the eukaryotic initiation factor 3f in pancreatic cancer.
Doldan A; Chandramouli A; Shanas R; Bhattacharyya A; Cunningham JT; Nelson MA; Shi J
Mol Carcinog; 2008 Mar; 47(3):235-44. PubMed ID: 17918192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
